NYSEAMERICAN:XXII - 22nd Century Group Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding 22nd Century Group Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.94 -0.04 (-4.08 %) (As of 02/20/2020 12:33 PM ET) Add Compare Today's Range$0.93Now: $0.94▼$0.9850-Day Range N/A52-Week Range$0.70Now: $0.94▼$2.59Volume45,114 shsAverage Volume2.43 million shsMarket Capitalization$118.23 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email 22nd Century Group, Inc, a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM research cigarettes for use in independent clinical studies. Read More… Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryCannabis SectorMedical Current SymbolNYSEAMERICAN:XXII Previous SymbolAMEX:XXII CUSIPN/A CIKN/A Webhttp://www.xxiicentury.com/ Phone+1-716-2701523Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees82 Outstanding Shares125,773,000Market Cap$118.23 million Next Earnings Date3/4/2020 (Estimated) OptionableOptionable Receive XXII News and Ratings via Email Sign-up to receive the latest news and ratings for XXII and its competitors with MarketBeat's FREE daily newsletter. AMEX:XXII Rates by TradingView 22nd Century Group (NYSEAMERICAN:XXII) Frequently Asked Questions What is 22nd Century Group's stock symbol? 22nd Century Group trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XXII." How were 22nd Century Group's earnings last quarter? 22nd Century Group Inc (NYSEAMERICAN:XXII) posted its quarterly earnings data on Wednesday, November, 7th. The biotechnology company reported $0.04 EPS for the quarter. The biotechnology company had revenue of $6.26 million for the quarter. View 22nd Century Group's Earnings History. When is 22nd Century Group's next earnings date? 22nd Century Group is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for 22nd Century Group. What price target have analysts set for XXII? 1 equities research analysts have issued 1-year price objectives for 22nd Century Group's stock. Their forecasts range from $12.00 to $12.00. On average, they expect 22nd Century Group's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 1,184.0% from the stock's current price. View Analyst Price Targets for 22nd Century Group. What is the consensus analysts' recommendation for 22nd Century Group? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 22nd Century Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for 22nd Century Group. What are Wall Street analysts saying about 22nd Century Group stock? Here are some recent quotes from research analysts about 22nd Century Group stock: 1. According to Zacks Investment Research, "22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. " (10/12/2019) 2. Chardan Capital analysts commented, "We expect the Q1 rate to continue over the coming quarters. Cash at quarter end was $52 million, or almost 4 years of cash at the company’s current burn rate. However, investments in the hemp market, (see below), will lower the company’s cash balances modestly. Below the operating line, the company recognized a $3.0 million unrealized gain on the increase in value of its almost 1 million warrants of Aurora Cannabis. Aurora purchased the company’s stake in a combination of stock and warrants. All of the shares of Aurora were sold, but 22nd Century retained the warrants. In US dollars, Aurora trades at $8.60 per share and the exercise price of the warrants is $7.01 per share. The company is investing in the hemp market." (5/8/2019) Has 22nd Century Group been receiving favorable news coverage? Media coverage about XXII stock has trended very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. 22nd Century Group earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for 22nd Century Group. Are investors shorting 22nd Century Group? 22nd Century Group saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 18,790,000 shares, an increase of 8.5% from the January 15th total of 17,320,000 shares. Based on an average daily volume of 2,190,000 shares, the short-interest ratio is currently 8.6 days. Currently, 15.7% of the company's stock are short sold. View 22nd Century Group's Current Options Chain. Who are some of 22nd Century Group's key competitors? Some companies that are related to 22nd Century Group include Canopy Growth (WEED), Canopy Growth (CGC), Innovative Industrial Properties (IIPR), OrganiGram (OGI), Emblem (EMC), GrowGeneration (GRWG), ICC Labs (ICC), Bioventix (BVXP), KushCo (KSHB), mCig (MCIG), General Cannabis (CANN), Terra Tech (TRTC), Grow Capital (GRWC), Nemus Bioscience (NMUS) and United Cannabis (CNAB). What other stocks do shareholders of 22nd Century Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other 22nd Century Group investors own include Cara Therapeutics (CARA), Canopy Growth (CGC), Novavax (NVAX), Aurora Cannabis (ACB), Cronos Group (CRON), Terra Tech (TRTC), Micron Technology (MU), Zynerba Pharmaceuticals (ZYNE), GW Pharmaceuticals PLC- (GWPH) and Aurora Cannabis (ACBFF). Who are 22nd Century Group's key executives? 22nd Century Group's management team includes the folowing people: Mr. Henry Sicignano III, MBA, Pres, CEO & Director (Age 51)Mr. John T. Brodfuehrer, CFO & Treasurer (Age 61)Mr. Thomas L. James J.D., Esq., VP, Gen. Counsel & Sec. (Age 60)James Vail, Director of CommunicationsMr. James C. Morrison, Technical Advisor & Regulatory Affairs Consultant Who are 22nd Century Group's major shareholders? 22nd Century Group's stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (1.62%), Bank of New York Mellon Corp (0.38%), UBS Group AG (0.13%), Charter Trust Co. (0.11%), Ladenburg Thalmann Financial Services Inc. (0.10%) and Barclays PLC (0.09%). Company insiders that own 22nd Century Group stock include Clifford B Fleet and Thomas L James. View Institutional Ownership Trends for 22nd Century Group. Which institutional investors are selling 22nd Century Group stock? XXII stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc. and Bank of America Corp DE. View Insider Buying and Selling for 22nd Century Group. Which institutional investors are buying 22nd Century Group stock? XXII stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Ladenburg Thalmann Financial Services Inc., Raymond James Financial Services Advisors Inc., Barclays PLC, State Street Corp, Charter Trust Co., Strategic Advisors LLC and UBS Group AG. View Insider Buying and Selling for 22nd Century Group. How do I buy shares of 22nd Century Group? Shares of XXII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is 22nd Century Group's stock price today? One share of XXII stock can currently be purchased for approximately $0.93. How big of a company is 22nd Century Group? 22nd Century Group has a market capitalization of $117.55 million. 22nd Century Group employs 82 workers across the globe.View Additional Information About 22nd Century Group. What is 22nd Century Group's official website? The official website for 22nd Century Group is http://www.xxiicentury.com/. How can I contact 22nd Century Group? 22nd Century Group's mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The biotechnology company can be reached via phone at +1-716-2701523. MarketBeat Community Rating for 22nd Century Group (NYSEAMERICAN XXII)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 323 (Vote Outperform)Underperform Votes: 269 (Vote Underperform)Total Votes: 592MarketBeat's community ratings are surveys of what our community members think about 22nd Century Group and other stocks. Vote "Outperform" if you believe XXII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XXII will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2020 by MarketBeat.com StaffFeatured Article: VIX - Volatility Index
